Published in Neurology on January 12, 2010
Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. Brain (2010) 4.39
Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease. Ann Neurol (2011) 4.38
Amyloid-β associated cortical thinning in clinically normal elderly. Ann Neurol (2011) 2.57
β-Amyloid burden in healthy aging: regional distribution and cognitive consequences. Neurology (2012) 2.49
Diffusion tensor imaging and cognitive function in older adults with no dementia. Neurology (2011) 1.89
Relationships between β-amyloid and functional connectivity in different components of the default mode network in aging. Cereb Cortex (2011) 1.87
β-Amyloid affects frontal and posterior brain networks in normal aging. Neuroimage (2010) 1.68
Selective disruption of the cerebral neocortex in Alzheimer's disease. PLoS One (2010) 1.65
Not quite PIB-positive, not quite PIB-negative: slight PIB elevations in elderly normal control subjects are biologically relevant. Neuroimage (2011) 1.64
Neuroimaging markers for the prediction and early diagnosis of Alzheimer's disease dementia. Trends Neurosci (2011) 1.51
Amyloid imaging as a biomarker for cerebral β-amyloidosis and risk prediction for Alzheimer dementia. Neurobiol Aging (2011) 1.51
White matter hyperintensities and cerebral amyloidosis: necessary and sufficient for clinical expression of Alzheimer disease? JAMA Neurol (2013) 1.47
Surface-Based fMRI-Driven Diffusion Tractography in the Presence of Significant Brain Pathology: A Study Linking Structure and Function in Cerebral Palsy. PLoS One (2016) 1.41
What is normal in normal aging? Effects of aging, amyloid and Alzheimer's disease on the cerebral cortex and the hippocampus. Prog Neurobiol (2014) 1.29
Neuroimaging and other biomarkers for Alzheimer's disease: the changing landscape of early detection. Annu Rev Clin Psychol (2013) 1.28
Spatial patterns of brain amyloid-beta burden and atrophy rate associations in mild cognitive impairment. Brain (2011) 1.23
Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer's disease. Neuroimage Clin (2013) 1.21
Accelerating cortical thinning: unique to dementia or universal in aging? Cereb Cortex (2012) 1.20
Selective worsening of brain injury biomarker abnormalities in cognitively normal elderly persons with β-amyloidosis. JAMA Neurol (2013) 1.20
Retinal vascular biomarkers for early detection and monitoring of Alzheimer's disease. Transl Psychiatry (2013) 1.19
Classification of amyloid-positivity in controls: comparison of visual read and quantitative approaches. Neuroimage (2013) 1.17
Covarying alterations in Aβ deposition, glucose metabolism, and gray matter volume in cognitively normal elderly. Hum Brain Mapp (2012) 1.17
Localized hippocampus measures are associated with Alzheimer pathology and cognition independent of total hippocampal volume. Neurobiol Aging (2011) 1.07
Effects of age and β-amyloid on cognitive changes in normal elderly people. Neurobiol Aging (2012) 1.06
A blood-based predictor for neocortical Aβ burden in Alzheimer's disease: results from the AIBL study. Mol Psychiatry (2013) 1.03
Amyloid PET in clinical practice: Its place in the multidimensional space of Alzheimer's disease. Neuroimage Clin (2013) 1.02
Contemplating Alzheimer's disease and the contribution of white matter hyperintensities. Curr Neurol Neurosci Rep (2013) 1.02
Iatrogenic risk factors for Alzheimer's disease: surgery and anesthesia. J Alzheimers Dis (2010) 1.00
Using Pittsburgh Compound B for in vivo PET imaging of fibrillar amyloid-beta. Adv Pharmacol (2012) 0.94
Differential effects of age and history of hypertension on regional brain volumes and iron. Neuroimage (2010) 0.94
Enrichment and stratification for predementia Alzheimer disease clinical trials. PLoS One (2012) 0.93
Emerging β-amyloid pathology and accelerated cortical atrophy. JAMA Neurol (2014) 0.93
Staging Alzheimer's disease progression with multimodality neuroimaging. Prog Neurobiol (2011) 0.92
Neuroimaging biomarkers of neurodegenerative diseases and dementia. Semin Neurol (2013) 0.92
Disclosure of amyloid imaging results to research participants: has the time come? Alzheimers Dement (2013) 0.91
Association of gray matter atrophy with age, β-amyloid, and cognition in aging. Cereb Cortex (2013) 0.91
The role of hippocampal iron concentration and hippocampal volume in age-related differences in memory. Cereb Cortex (2012) 0.90
In vivo human amyloid imaging. Curr Alzheimer Res (2011) 0.90
Does amyloid deposition produce a specific atrophic signature in cognitively normal subjects? Neuroimage Clin (2013) 0.89
Is amyloid-β harmful to the brain? Insights from human imaging studies. Brain (2015) 0.88
Role of structural MRI in Alzheimer's disease. Alzheimers Res Ther (2010) 0.88
PET amyloid-beta imaging in preclinical Alzheimer's disease. Biochim Biophys Acta (2011) 0.87
The transitional association between β-amyloid pathology and regional brain atrophy. Alzheimers Dement (2014) 0.87
Cholinergic basal forebrain atrophy predicts amyloid burden in Alzheimer's disease. Neurobiol Aging (2013) 0.86
Cortical surface-based analysis reduces bias and variance in kinetic modeling of brain PET data. Neuroimage (2013) 0.86
Should we disclose amyloid imaging results to cognitively normal individuals? Neurodegener Dis Manag (2013) 0.86
Astrocytosis measured by ¹¹C-deprenyl PET correlates with decrease in gray matter density in the parahippocampus of prodromal Alzheimer's patients. Eur J Nucl Med Mol Imaging (2014) 0.86
Amyloid burden in the hippocampus and default mode network: relationships with gray matter volume and cognitive performance in mild stage Alzheimer disease. Medicine (Baltimore) (2015) 0.85
β-Amyloid is associated with aberrant metabolic connectivity in subjects with mild cognitive impairment. J Cereb Blood Flow Metab (2014) 0.85
Atrophy rates in asymptomatic amyloidosis: implications for Alzheimer prevention trials. PLoS One (2013) 0.85
Impact of apolipoprotein E4-cerebrospinal fluid β-amyloid interaction on hippocampal volume loss over 1 year in mild cognitive impairment. Alzheimers Dement (2011) 0.85
Structural brain alterations before mild cognitive impairment in ADNI: validation of volume loss in a predefined antero-temporal region. J Alzheimers Dis (2012) 0.83
Parallel ICA of FDG-PET and PiB-PET in three conditions with underlying Alzheimer's pathology. Neuroimage Clin (2014) 0.83
New treatment strategies for Alzheimer's disease: is there a hope? Indian J Med Res (2013) 0.82
Multimodal MRI-based Imputation of the Aβ+ in Early Mild Cognitive Impairment. Ann Clin Transl Neurol (2014) 0.81
Structural imaging in early pre-states of dementia. Biochim Biophys Acta (2011) 0.81
Protein aggregation containing β-amyloid, α-synuclein and hyperphosphorylated τ in cultured cells of hippocampus, substantia nigra and locus coeruleus after rotenone exposure. BMC Neurosci (2010) 0.81
Neuroimaging predictors of brain amyloidosis in mild cognitive impairment. Ann Neurol (2013) 0.81
Aβ-related hyperactivation in frontoparietal control regions in cognitively normal elderly. Neurobiol Aging (2015) 0.80
Basal forebrain atrophy correlates with amyloid β burden in Alzheimer's disease. Neuroimage Clin (2014) 0.80
Differences in functional brain connectivity alterations associated with cerebral amyloid deposition in amnestic mild cognitive impairment. Front Aging Neurosci (2015) 0.80
Cerebrospinal Fluid Levels of Amyloid Beta 1-43 Mirror 1-42 in Relation to Imaging Biomarkers of Alzheimer's Disease. Front Aging Neurosci (2017) 0.79
Brain structure and function as mediators of the effects of amyloid on memory. Neurology (2015) 0.79
APOE ε4 genotype predicts memory for everyday activities. Neuropsychol Dev Cogn B Aging Neuropsychol Cogn (2015) 0.78
In vivo visualization of tau deposits in corticobasal syndrome by 18F-THK5351 PET. Neurology (2016) 0.77
Non-Alzheimer's disease-related memory impairment and dementia. Dialogues Clin Neurosci (2013) 0.77
Time to Amyloid Positivity and Preclinical Changes in Brain Metabolism, Atrophy, and Cognition: Evidence for Emerging Amyloid Pathology in Alzheimer's Disease. Front Neurosci (2017) 0.76
Prefrontal Lobe Brain Reserve Capacity with Resistance to Higher Global Amyloid Load and White Matter Hyperintensity Burden in Mild Stage Alzheimer's Disease. PLoS One (2016) 0.76
Immunotherapy for the treatment of Alzheimer's disease: amyloid-β or tau, which is the right target? Immunotargets Ther (2013) 0.75
A review of neuroimaging biomarkers of Alzheimer's disease. Neurol Asia (2013) 0.75
Basal Forebrain Atrophy Contributes to Allocentric Navigation Impairment in Alzheimer's Disease Patients. Front Aging Neurosci (2015) 0.75
PET imaging of garbage protein in Alzheimer's disease: does it require reappraisal of brain PET analysis? Eur J Nucl Med Mol Imaging (2014) 0.75
Amyloid burden in cognitively normal elderly is associated with preferential hippocampal subfield volume loss. J Alzheimers Dis (2015) 0.75
Recent Progress in Alzheimer's Disease Research, Part 3: Diagnosis and Treatment. J Alzheimers Dis (2017) 0.75
Hippocampal Amyloid Burden with Downstream Fusiform Gyrus Atrophy Correlate with Face Matching Task Scores in Early Stage Alzheimer's Disease. Front Aging Neurosci (2016) 0.75
Pro: Can biomarkers be gold standards in Alzheimer's disease? Alzheimers Res Ther (2010) 0.75
Role of Hybrid Brain Imaging in Neuropsychiatric Disorders. Diagnostics (Basel) (2015) 0.75
Local and distant relationships between amyloid, tau and neurodegeneration in Alzheimer's Disease. Neuroimage Clin (2017) 0.75
The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature (1987) 17.08
Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci U S A (1985) 16.10
Imaging beta-amyloid burden in aging and dementia. Neurology (2007) 7.70
Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol (1999) 7.69
Neuronal origin of a cerebral amyloid: neurofibrillary tangles of Alzheimer's disease contain the same protein as the amyloid of plaque cores and blood vessels. EMBO J (1985) 6.24
Creutzfeldt-Jakob disease: patterns of worldwide occurrence and the significance of familial and sporadic clustering. Ann Neurol (1979) 5.53
Rapid induction of Alzheimer A beta amyloid formation by zinc. Science (1994) 5.34
Identification, biogenesis, and localization of precursors of Alzheimer's disease A4 amyloid protein. Cell (1989) 4.99
Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron (2001) 4.42
Activation of memory circuits during cue-elicited cocaine craving. Proc Natl Acad Sci U S A (1996) 4.31
In vivo mapping of gray matter loss with voxel-based morphometry in mild Alzheimer's disease. Neuroimage (2001) 3.87
Childhood outcomes after prescription of antibiotics to pregnant women with spontaneous preterm labour: 7-year follow-up of the ORACLE II trial. Lancet (2008) 3.65
Aggregation and secondary structure of synthetic amyloid beta A4 peptides of Alzheimer's disease. J Mol Biol (1991) 3.33
A4 amyloid protein deposition and the diagnosis of Alzheimer's disease: prevalence in aged brains determined by immunocytochemistry compared with conventional neuropathologic techniques. Neurology (1988) 3.28
Amyloid A4 protein and its precursor in Down's syndrome and Alzheimer's disease. N Engl J Med (1989) 3.24
Precursor of amyloid protein in Alzheimer disease undergoes fast anterograde axonal transport. Proc Natl Acad Sci U S A (1990) 3.13
Analysis of heterogeneous A4 peptides in human cerebrospinal fluid and blood by a newly developed sensitive Western blot assay. J Biol Chem (1996) 3.10
Distinct sites of intracellular production for Alzheimer's disease A beta40/42 amyloid peptides. Nat Med (1997) 2.95
A magnetic resonance imaging study of white matter lesions in depression and Alzheimer's disease. Br J Psychiatry (1996) 2.75
Abeta deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease. Neuropsychologia (2008) 2.58
The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease. Int Psychogeriatr (2009) 2.54
Determinants of diagnostic investigation sensitivities across the clinical spectrum of sporadic Creutzfeldt-Jakob disease. Brain (2006) 2.54
Subacute spongiform encephalopathy (Creutzfeldt-Jakob disease). The nature and progression of spongiform change. Brain (1978) 2.49
Childhood outcomes after prescription of antibiotics to pregnant women with preterm rupture of the membranes: 7-year follow-up of the ORACLE I trial. Lancet (2008) 2.42
Packaging of prions into exosomes is associated with a novel pathway of PrP processing. J Pathol (2007) 2.31
Cu(II) potentiation of alzheimer abeta neurotoxicity. Correlation with cell-free hydrogen peroxide production and metal reduction. J Biol Chem (1999) 2.30
The amyloid precursor protein of Alzheimer's disease in the reduction of copper(II) to copper(I) Science (1996) 2.29
Ultrastructural morphology of amyloid fibrils from neuritic and amyloid plaques. Acta Neuropathol (1983) 2.23
Identification, transmembrane orientation and biogenesis of the amyloid A4 precursor of Alzheimer's disease. EMBO J (1988) 2.23
A heparin-binding domain in the amyloid protein precursor of Alzheimer's disease is involved in the regulation of neurite outgrowth. J Neurosci (1994) 2.19
Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography. J Neurol Neurosurg Psychiatry (2008) 2.12
Amyloid, aluminium and the aetiology of Alzheimer's disease. Med J Aust (1995) 2.09
Behavioral and psychological symptoms of dementia in developing countries. Int Psychogeriatr (2004) 2.03
Oral transmission of kuru, Creutzfeldt-Jakob disease, and scrapie to nonhuman primates. J Infect Dis (1980) 1.96
Patterns of cortical thinning in the language variants of frontotemporal lobar degeneration. Neurology (2009) 1.95
The promoter of Alzheimer's disease amyloid A4 precursor gene. EMBO J (1988) 1.92
Substitutions of hydrophobic amino acids reduce the amyloidogenicity of Alzheimer's disease beta A4 peptides. J Mol Biol (1992) 1.90
Apolipoprotein E, cholesterol metabolism, diabetes, and the convergence of risk factors for Alzheimer's disease and cardiovascular disease. Mol Psychiatry (2006) 1.88
A comparative analysis of leucine-rich repeat kinase 2 (Lrrk2) expression in mouse brain and Lewy body disease. Neuroscience (2007) 1.86
The familial occurrence of Creutzfeldt-Jakob disease and Alzheimer's disease. Brain (1981) 1.80
Chemical andropause and amyloid-beta peptide. JAMA (2001) 1.75
Surgical treatment and risk of sporadic Creutzfeldt-Jakob disease: a case-control study. Lancet (1999) 1.74
Severe deep white matter lesions and outcome in elderly patients with major depressive disorder: follow up study. BMJ (1998) 1.73
The amyloid protein precursor of Alzheimer's disease is a mediator of the effects of nerve growth factor on neurite outgrowth. Neuron (1992) 1.72
Hyponatraemia and selective serotonin re-uptake inhibitors in elderly patients. Int J Geriatr Psychiatry (2001) 1.69
11C-PiB PET studies in typical sporadic Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry (2009) 1.66
Syndromes of amyotrophic lateral sclerosis and dementia: relation to transmissible Creutzfeldt-Jakob disease. Ann Neurol (1983) 1.65
Alzheimer's disease amyloid-beta binds copper and zinc to generate an allosterically ordered membrane-penetrating structure containing superoxide dismutase-like subunits. J Biol Chem (2001) 1.64
A4 protein in Alzheimer's disease: primary and secondary cellular events in extracellular amyloid deposition. J Neuropathol Exp Neurol (1989) 1.62
Nomenclature of amyloid fibril proteins. Report from the meeting of the International Nomenclature Committee on Amyloidosis, August 8-9, 1998. Part 1. Amyloid (1999) 1.59
Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study. Brain (2012) 1.58
Crystal structure of the N-terminal, growth factor-like domain of Alzheimer amyloid precursor protein. Nat Struct Biol (1999) 1.56
Has publication of the results of the ORACLE Children Study changed practice in the UK? BJOG (2010) 1.55
Genes contributing to Alzheimer's disease. Mol Psychiatry (1996) 1.55
Oestrogen replacement therapy may improve memory functioning in the absence of APOE epsilon4. J Alzheimers Dis (2004) 1.55
Rates of diagnostic transition and cognitive change at 18-month follow-up among 1,112 participants in the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (AIBL). Int Psychogeriatr (2013) 1.53
High-speed nonlinear finite element analysis for surgical simulation using graphics processing units. IEEE Trans Med Imaging (2008) 1.53
Relationship between testosterone, sex hormone binding globulin and plasma amyloid beta peptide 40 in older men with subjective memory loss or dementia. J Alzheimers Dis (2003) 1.52
Alzheimer's disease amyloid-beta peptide modulates apolipoprotein E isoform specific receptor binding. J Alzheimers Dis (2005) 1.51
Predictors of rapid cognitive decline in Alzheimer's disease: results from the Australian imaging, biomarkers and lifestyle (AIBL) study of ageing. Int Psychogeriatr (2011) 1.49
Aqueous dissolution of Alzheimer's disease Abeta amyloid deposits by biometal depletion. J Biol Chem (1999) 1.48
Regulation of amyloid protein precursor (APP) binding to collagen and mapping of the binding sites on APP and collagen type I. J Biol Chem (1996) 1.48
Eradication programme for bovine viral diarrhoea virus in Orkney 2001 to 2008. Vet Rec (2010) 1.47
Mechanism of the cleavage specificity of Alzheimer's disease gamma-secretase identified by phenylalanine-scanning mutagenesis of the transmembrane domain of the amyloid precursor protein. Proc Natl Acad Sci U S A (1999) 1.46
A4 amyloid protein immunoreactivity is present in Alzheimer's disease neurofibrillary tangles. Neurosci Lett (1989) 1.45
Influence of BDNF Val66Met on the relationship between physical activity and brain volume. Neurology (2014) 1.44
11C-PIB binding is increased in patients with cerebral amyloid angiopathy-related hemorrhage. Neurology (2010) 1.43
Localization of the putative precursor of Alzheimer's disease-specific amyloid at nuclear envelopes of adult human muscle. EMBO J (1988) 1.43
Amyloid precursor protein (APP) and beta A4 amyloid in the etiology of Alzheimer's disease: precursor-product relationships in the derangement of neuronal function. Brain Pathol (1991) 1.43
Cerebral microhemorrhage and brain β-amyloid in aging and Alzheimer disease. Neurology (2011) 1.43
Tacrine in Alzheimer's disease. Lancet (1989) 1.41
Localization of Alzheimer beta A4 amyloid precursor protein at central and peripheral synaptic sites. Brain Res (1991) 1.41
Pharmacological treatment of cognitive deficits in Alzheimer's disease. Med J Aust (2001) 1.40
Preclinical lesions and their progression in the experimental spongiform encephalopathies (kuru and Creutzfeldt-Jakob disease) in primates. J Neuropathol Exp Neurol (1977) 1.39
Does risperidone improve verbal working memory in treatment-resistant schizophrenia? Am J Psychiatry (1997) 1.39
Plasma apolipoprotein E and Alzheimer disease risk: the AIBL study of aging. Neurology (2011) 1.37
The amyloid precursor protein of Alzheimer's disease is released by human platelets. J Biol Chem (1990) 1.36
Evidence for and against the transmissibility of Alzheimer disease. Neurology (1980) 1.34
The beta A4 amyloid precursor protein binding to copper. FEBS Lett (1994) 1.34
A novel zinc(II) binding site modulates the function of the beta A4 amyloid protein precursor of Alzheimer's disease. J Biol Chem (1993) 1.33
Preclinical trials in autosomal dominant AD: implementation of the DIAN-TU trial. Rev Neurol (Paris) (2013) 1.33